Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.

Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Zúñiga-Pflücker JC, Lu C, van den Brink MR.

Nat Biotechnol. 2008 Apr;26(4):453-61. doi: 10.1038/nbt1395. Epub 2008 Mar 30.

PMID:
18376399
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Ghosh A, Holland AM, van den Brink MR.

Immunol Rev. 2014 Jan;257(1):226-36. doi: 10.1111/imr.12142. Review.

PMID:
24329800
[PubMed - indexed for MEDLINE]
3.

Redirected tumor-specific allogeneic T cells for universal treatment of cancer.

Marcus A, Waks T, Eshhar Z.

Blood. 2011 Jul 28;118(4):975-83. doi: 10.1182/blood-2011-02-334284. Epub 2011 Jun 7.

PMID:
21653325
[PubMed - indexed for MEDLINE]
Free Article
4.

Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.

Waller EK, Ship AM, Mittelstaedt S, Murray TW, Carter R, Kakhniashvili I, Lonial S, Holden JT, Boyer MW.

Blood. 1999 Nov 1;94(9):3222-33.

PMID:
10556211
[PubMed - indexed for MEDLINE]
Free Article
5.

Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease.

Gao L, Yang TH, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ.

Blood. 1999 Nov 1;94(9):2999-3006.

PMID:
10556182
[PubMed - indexed for MEDLINE]
Free Article
6.
7.

Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.

Spaapen R, van den Oudenalder K, Ivanov R, Bloem A, Lokhorst H, Mutis T.

Clin Cancer Res. 2007 Jul 1;13(13):4009-15.

PMID:
17606735
[PubMed - indexed for MEDLINE]
Free Article
8.

The allogeneic response and tumor immunity.

Fabre JW.

Nat Med. 2001 Jun;7(6):649-52. Review.

PMID:
11385492
[PubMed - indexed for MEDLINE]
9.
10.

Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.

Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA.

Biol Blood Marrow Transplant. 2001;7(10):532-42.

PMID:
11760085
[PubMed - indexed for MEDLINE]
11.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
[PubMed - indexed for MEDLINE]
12.

Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.

Ji YH, Weiss L, Zeira M, Abdul-Hai A, Reich S, Schuger L, Slavin S.

Bone Marrow Transplant. 2003 Sep;32(5):495-504.

PMID:
12942096
[PubMed - indexed for MEDLINE]
13.
14.

Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.

Waller EK, Giver CR, Rosenthal H, Somani J, Langston AA, Lonial S, Roback JD, Li JM, Hossain MS, Redei I.

Blood Cells Mol Dis. 2004 Nov-Dec;33(3):233-7.

PMID:
15528137
[PubMed - indexed for MEDLINE]
15.

New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.

Waller EK, Boyer M.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S20-4.

PMID:
10933181
[PubMed - indexed for MEDLINE]
16.

Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.

Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1679-87. doi: 10.1016/j.bbmt.2011.05.012. Epub 2011 May 25.

PMID:
21664472
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells.

Distler E, Bloetz A, Albrecht J, Asdufan S, Hohberger A, Frey M, Schnürer E, Thomas S, Theobald M, Hartwig UF, Herr W.

Haematologica. 2011 Jul;96(7):1024-32. doi: 10.3324/haematol.2010.037481. Epub 2011 Apr 12.

PMID:
21486863
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Genetic engineering of T cell specificity for immunotherapy of cancer.

Willemsen RA, Debets R, Chames P, Bolhuis RL.

Hum Immunol. 2003 Jan;64(1):56-68. Review.

PMID:
12507815
[PubMed - indexed for MEDLINE]
19.
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk